Product Description
For osteoarthritis (OA) of the knee. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01207115)
Mechanisms of Action: HRH3 Modulator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: AbbVie
Company Location: Eastern America
Company Founding Year: 2013
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Osteoarthritis, Knee|Neuropathic Pain|Neuralgia
Phase 1: Parasomnias
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01124851 |
M11-685 | P1 |
Completed |
Parasomnias |
2011-04-01 |
2019-03-19 |
Treatments |
|
NCT01579279 |
M11-210 | P2 |
Terminated |
Neuropathic Pain|Neuralgia |
2012-05-01 |
2019-03-19 |
Treatments |
|
NCT01444365 |
M13-237 | P2 |
Completed |
Osteoarthritis, Knee |
2012-04-01 |
2019-03-19 |
Treatments |
|
NCT01207115 |
M10-889 | P2 |
Completed |
Osteoarthritis, Knee |
2011-05-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|